Antibody mimetics: promising complementary agents to animal-sourced antibodies

References

• Ahlgren S, Wållberg H, Tran TA, et al. (2009). Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine. J Nuclear Med, 50, 781–9
   PubMed Web of Science ®Google Scholar
• Arnoux B, Ducruix A, Prange T. (2002). Anisotropic behaviour of the C-terminal Kunitz-type domain of the 3 chain of human type VI collagen at atomic resolution (0.9 A). Acta Crystallographica D: Biol Crystallograph, 58, 1252–4
   PubMed Web of Science ®Google Scholar
• Balsitis S, Dick F, Dyson N, Lambert PF. (2006). Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res, 66, 9393–400
   PubMed Web of Science ®Google Scholar
• Beuttler J, Rothdiener M, Müller D, et al. (2009). Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjugate Chem, 20, 1201–8
   PubMed Web of Science ®Google Scholar
• Cai S, Singh BR. (2007). Strategies to design inhibitors of clostridium botulinum neurotoxins. Infect Disord Drug Target, 7, 47–57
   PubMedGoogle Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. (2009). Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol, 157, 220–33
   PubMed Web of Science ®Google Scholar
• Covagen, Advanced Biopharmaceuticals. Covagen utilizes the unique versatility of Fynomers to create next generation biologic. Available from: http://www.covagen.com/index.php?id=118 [last accessed 21 Jun 2013].
   Google Scholar
• Ebersbach H, Fiedler E, Scheuermann T, et al. (2007). Affilin–novel binding molecules based on human γ-b-crystallin, an all β-sheet protein. J Mol Biol, 372, 172–85
   PubMed Web of Science ®Google Scholar
• Eggenstein E, Eichinger A, Kim H-J, Skerra A. (2013). Structure-guided engineering of Anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy. J Struct Biol, 185, 203–14
   PubMed Web of Science ®Google Scholar
• Eyer F, Steimer W, Nitzsche T, et al. (2012). Intravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats. Toxicol Appl Pharmacol, 263, 352–9
   PubMed Web of Science ®Google Scholar
• Gao J, Li B, Li H, et al. (2009). Development and characterization of a fully functional small anti-HER2 antibody. BMB Rep, 42, 636–41
   PubMed Web of Science ®Google Scholar
• Gebauer M, Schiefner A, Matschiner G, Skerra A. (2012). Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J Mol Biol, 425, 780–802
   PubMed Web of Science ®Google Scholar
• Göstring L, Malm M, Höidén-Guthenberg I, et al. (2012). Cellular effects of HER3-specific affibody molecules. PLoS One, 7, e40023
   PubMed Web of Science ®Google Scholar
• Grabulovski D, Kaspar M, Neri D. (2007). A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem, 282, 3196–204
   PubMed Web of Science ®Google Scholar
• Hey T, Fiedler E, Rudolph R, Fiedler M. (2005). Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol, 23, 514–22
   PubMed Web of Science ®Google Scholar
• Hirano T. (1992). Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol, 62, S60–5
   PubMedGoogle Scholar
• Jefferis R. (2009). Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov, 8, 226–34
   PubMed Web of Science ®Google Scholar
• Jeong KJ, Mabry R, Georgiou G. (2005). Avimers hold their own. Nature Biotechnol, 23, 1493–4
   PubMed Web of Science ®Google Scholar
• Khalili H, Godwin A, Choi J-w, et al. (2013). Fab-PEG-Fab as a potential antibody mimetic. Bioconjugate Chem, 24, 1870–82
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–7
   PubMed Web of Science ®Google Scholar
• Koide A, Koide S. (2007). Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Meth Mol Biol, 352, 95–109
   PubMedGoogle Scholar
• Krehenbrink M, Chami M, Guilvout I, et al. (2008). Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J Mol Biol, 383, 1058–68
   PubMed Web of Science ®Google Scholar
• Ladner RC. (2007). Antibodies cut down to size. Nat Biotechnol, 25, 875–7
   PubMed Web of Science ®Google Scholar
• Lee CM, Shrieve DC, Zempolich KA, et al. (2005). Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol, 99, 415–21
   PubMed Web of Science ®Google Scholar
• Linsley PS, Golstein P. (1996). Lymphocyte activation: T-cell regulation by CTLA-4. Curr Biol, 6, 398–400
   PubMed Web of Science ®Google Scholar
• Lipovšek D. (2011). Adnectins: engineered target-binding protein therapeutics. Protein Eng Design Select, 24, 3–9
   PubMed Web of Science ®Google Scholar
• Löfblom J, Feldwisch J, Tolmachev V, et al. (2010). Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett, 584, 2670–80
   PubMed Web of Science ®Google Scholar
• Löfblom J, Frejd FY. (2011). Alternative scaffolds as bispecific antibody mimetics. In: Kontermann RE, ed. Bispecific antibodies. Berlin Heidelberg: Springer-Verlag, 115–33
   Google Scholar
• Mamluk R, Carvajal IM, Morse BA, et al. (2010). Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. Landes Biosci, 2, 199–208
   Google Scholar
• Mirecka EA, Hey T, Fiedler U, et al. (2009). Affilin molecules selected against the human papillomavirus E7 protein inhibit the proliferation of target cells. J Mol Biol, 390, 710–21
   PubMed Web of Science ®Google Scholar
• Mouratou B, Schaeffer F, Guilvout I, et al. (2007). Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD. Proc Natl Acad Sci, 104, 17983–8
   PubMed Web of Science ®Google Scholar
• Murali R, Greene MI. (2012). Structure based antibody-like peptidomimetics. Pharmaceuticals, 5, 209–35
   Google Scholar
• Murphree AL, Benedict WF. (1984). Retinoblastoma: clues to human oncogenesis. Science, 223, 1028–33
   PubMed Web of Science ®Google Scholar
• Qiu X-Q, Wang H, Cai B, et al. (2007). Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol, 25, 921–9
   PubMed Web of Science ®Google Scholar
• Renberg B, Nordin J, Merca A, et al. (2007). Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats. J Prot Res, 6, 171–9
   PubMed Web of Science ®Google Scholar
• Romero PA, Arnold FH. (2009). Exploring protein fitness landscapes by directed evolution. Nat Rev Mol Cell Biol, 10, 866–76
   PubMed Web of Science ®Google Scholar
• Rusconi CP, Roberts JD, Pitoc GA, et al. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnol, 22, 1423–8
   PubMed Web of Science ®Google Scholar
• Russell WMS, Burch RL, Hume CW. (1959). The principles of humane experimental technique. London: Methuen & Co
   Google Scholar
• Schlatter D, Brack S, Banner DW, et al. (2012). Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. Landes Biosci, 4, 497–508
   Google Scholar
• Schlehuber S, Skerra A. (2005). Anticalins as an alternative to antibody technology. Expert Opin Biol Therap, 5, 1453–62
   PubMed Web of Science ®Google Scholar
• Schönfeld D, Matschiner G, Chatwell L, et al. (2009). An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci, 106, 8198–203
   PubMed Web of Science ®Google Scholar
• Schweizer A, Rusert P, Berlinger L, et al. (2008). CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog, 4, e1000109
   PubMed Web of Science ®Google Scholar
• Scott CJ, Taggart CC. (2010). Biologic protease inhibitors as novel therapeutic agents. Biochimie, 92, 1681–8
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK, et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol, 20, 1215–21
   PubMed Web of Science ®Google Scholar
• Silverman J, Lu Q, Bakker A, et al. (2005). Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nature Biotechnol, 23, 1556–61
   PubMed Web of Science ®Google Scholar
• Skerra A. (2001). ‘Anticalins’: a new class of engineered ligand-binding proteins with antibody-like properties. Rev Mol Biotechnol, 74, 257–75
   Google Scholar
• Skerra A. (2008). Alternative binding proteins: anticalins–harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J, 275, 2677–83
   PubMed Web of Science ®Google Scholar
• Stumpp MT, Amstutz P. (2007). DARPins: a true alternative to antibodies. Curr Opin Drug Discov Dev, 10, 153–9
   PubMed Web of Science ®Google Scholar
• Suffredini AF, Fantuzzi G, Badolato R, et al. (1999). New insights into the biology of the acute phase response. J Clin Immunol, 19, 203–14
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Orlova A, Pehrson R, et al. (2007). Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res, 67, 2773–82
   PubMed Web of Science ®Google Scholar
• Tran T, Engfeldt T, Orlova A, et al. (2007). 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjugate Chem, 18, 1956–64
   PubMed Web of Science ®Google Scholar
• Wållberg H, Löfdahl P-Å, Tschapalda K, et al. (2011). Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. Protein Expres Purif, 76, 127–35
   PubMed Web of Science ®Google Scholar
• Wurch T, Pierré A, Depil S. (2012). Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol, 30, 575–82
   PubMed Web of Science ®Google Scholar
• Zielinski R, Lyakhov I, Jacobs A, et al. (2009). Affitoxin–a novel recombinant, HER2-specific, anti-cancer agent for targeted therapy of HER2-positive tumors. J Immunotherapy (Hagerstown, Md: 1997), 32, 817–25
   PubMed Web of Science ®Google Scholar